Table 1.
Baseline Clinical Characteristics of the Study Population
|
LAAO Group (N=50) |
OAC Group (N=48) |
P Value | |
|---|---|---|---|
| Age | 69.6±7.8 | 69.1±5.7 | 0.72 |
| Age≥75 | 15 (30.0) | 6 (12.5) | 0.035 |
| Body mass index | 30.1±5.7 | 31.0±6.0 | 0.43 |
| Male patients | 37 (74.0) | 34 (70.8) | 0.73 |
| Nonparoxysmal AF | 38 (76.0) | 29 (60.4) | 0.10 |
| Hypertension | 37 (74.0) | 36 (75.0) | 0.91 |
| Dyslipidemia | 23 (46.0) | 25 (52.1) | 0.55 |
| Obstructive sleep apnea | 10 (20.0) | 8 (16.7) | 0.67 |
| Diabetes mellitus | 12 (24.0) | 9 (18.8) | 0.53 |
| History of TIA or stroke | 9 (18.0) | 4 (8.3) | 0.16 |
| Coronary artery disease | 22 (44.0) | 14 (29.2) | 0.13 |
| CHA2DS2 score | 1.92±1.09 | 1.33±0.95 | 0.006 |
| CHA2DS2‐VASc score | 3.30±1.43 | 2.73±1.25 | 0.038 |
| HAS‐BLED score | 2.12±1.2 | 2.00±1.0 | 0.59 |
| Number of ablation procedures | 1.94±1.38 | 1.60±0.82 | 0.15 |
| LAA isolation | 17 (34.0) | 18 (37.5) | 0.71 |
| Beta‐blockers | 23 (46.0) | 28 (58.3) | 0.22 |
| B‐type natriuretic peptide, pg/mL | 235.0±53.3 | 212.4±131.2 | 0.26 |
CHA2DS2 indicates congestive heart failure, hypertension, age (>65=1 point, >75=2 points), diabetes mellitus, previous stroke/transient ischemic attack (2 points); CHA2DS2‐VASc, congestive heart failure, hypertension, age≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65–74 years, sex category; HAS‐BLED, hypertension, abnormal liver/renal function, stroke history, bleeding history or predisposition, labile international normalized ratio, elderly, drug/alcohol usage; LAA, left atrial appendage; LAA, left atrial appendage occlusion; OAC, oral anticoagulation; and TIA, transient ischemic attack.